Mediolanum International Funds Ltd Has $22.28 Million Position in Zoetis Inc. $ZTS

Mediolanum International Funds Ltd increased its stake in Zoetis Inc. (NYSE:ZTS) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 191,495 shares of the company’s stock after purchasing an additional 14,539 shares during the period. Mediolanum International Funds Ltd’s holdings in Zoetis were worth $22,277,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Prosperity Bancshares Inc bought a new position in Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at $30,000. Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Holos Integrated Wealth LLC acquired a new position in shares of Zoetis during the fourth quarter valued at $32,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Zoetis during the fourth quarter valued at $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 in the last ninety days. 0.22% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZTS. JPMorgan Chase & Co. decreased their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HSBC dropped their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Stifel Nicolaus lowered their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $120.83.

Zoetis Stock Down 0.6%

NYSE:ZTS opened at $76.44 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $160.48. The stock’s fifty day simple moving average is $77.33 and its 200-day simple moving average is $106.03. The firm has a market capitalization of $32.05 billion, a P/E ratio of 12.68, a P/E/G ratio of 1.19 and a beta of 0.75.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the company posted $1.48 EPS. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis was named as title sponsor of PawsitiveIntelligence.ai, adding a small brand-visibility and industry-partnership angle. Pawsitive Holdings Announces Zoetis as Title Sponsor of PawsitiveIntelligence.ai
• Positive Sentiment: Some commentary argued Zoetis offers an attractive risk-reward setup, suggesting a more constructive long-term view despite recent volatility. Zoetis: An Attractive Risk-Reward Opportunity
• Neutral Sentiment: Zoetis’ upcoming second-quarter earnings report is getting attention, with analysts expecting modest growth and investors watching for updated guidance and commentary on diagnostics demand. Zoetis Earnings Preview: What to Expect
• Neutral Sentiment: Zoetis announced it will acquire VitalRADS, a veterinary teleradiology platform, which could support its diagnostics strategy and AI-enabled offerings. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
• Negative Sentiment: Multiple law firms issued reminders and investor alerts tied to a securities class action against Zoetis, reinforcing concerns about litigation risk and possible reputational damage. Deadline Alert for CALX, AVAV, ZTS, LCID
• Negative Sentiment: Additional class-action notices specifically target Zoetis shareholders, underscoring that the lawsuit remains an active overhang for the stock. ZTS Shareholder Alert
• Negative Sentiment: The legal backdrop follows earlier reports alleging investor harm and reminding shareholders of the same July 27 deadline, keeping sentiment cautious. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.